1
Raymond Armand Firestone, Gene Michael Dubowchik: Lysosomal enzyme-cleavable antitumor drug conjugates. Bristol Myers Squibb Co, James M Bogden, Thomas R Savitsky, Audrey F Sher, April 10, 2001: US06214345 (207 worldwide citation)

The present invention relates to drug-ligand conjugates wherein the drug is linked to the ligand through a protein peptide linker and a connector, a process for the preparation of the conjugates, method of controlling the growth of undesirable cells, pharmaceutical compositions, and intermediates th ...


2
Natesan Murugesan: Substituted biphenyl isoxazole sulfonamides. Bristol Myers Squibb Company, Suzanne E Babajko, March 18, 1997: US05612359 (195 worldwide citation)

Compounds of the formula ##STR1## inhibit the activity of endothelin. The symbols are defined as follows: R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are each directly bonded to a ring carbon and are each independently


3
W Thompson Lawrence, Clair L Strohl Jr: Liquid removal system. Bristol-Myers Squibb, Thomas A O Rourke, October 21, 1997: US05678564 (189 worldwide citation)

The liquid removal system of the present invention is designed to permit efficient liquid removal as needed through the use of an interface device. The interface device is provided with a membrane which has and is capable of maintaining a vacuum on one side so that when liquid contacts the opposite ...


4
Kevin Cook, Paul Hickey, John D Cooper: Head center instrument and method of using the same. Bristol Myers Squibb Co, July 10, 2001: US06258097 (163 worldwide citation)

An orthopaedic instrument for comparing post-surgical joint geometry to pre-surgical joint geometry. The instrument has a head chuck which can be secured to the ball of a ball joint, and an arm having reference indicia thereon. Markings indicative of the pre-surgical joint geometry are made on the b ...


5
W Thompson Lawrence, Clair L Strohl Jr: Liquid removal system. Bristol-Myers Squibb, Thomas A O Rourke, June 15, 1999: US05911222 (159 worldwide citation)

A liquid removal system having an interface device and a vacuum source are described. The interface device has a porous membrane with an entrance zone on one side. The vacuum source maintains a vacuum on the side of the membrane opposite the entrance zone when the membrane is wetted. Liquid which co ...


6
Evan C Unger: Acoustically active drug delivery systems. Bristol Myers Squibb Medical Imaging, Woodcock Washburn, July 9, 2002: US06416740 (158 worldwide citation)

The present invention is directed to targeted therapeutic delivery systems comprising a gas or gaseous precursor filled microsphere wherein said gas or gaseous precursor filled microsphere comprises an oil, a surfactant, and a therapeutic compound. Methods of preparing the targeted therapeutic deliv ...


7
Steven Lee Meulink, Stephen R Rozow III: Assembly tool for prosthetic implant. Bristol Myers Squibb Co, Cary R Reeves, May 29, 2001: US06238435 (158 worldwide citation)

An instrument for seating taper junctions of modular implants engages two components and provides a sustained assembly force along the junction axis with great mechanical advantage. In one embodiment the instrument comprises a lever mechanism for generating the mechanical advantage. In another embod ...


8
John N Insall, Giles R Scuderi, Pascal Poilvache, Robert A Hodorek, David J Krueger: Apparatus and method for knee implantation. Bristol Myers Squibb Company, Cary R Reeves, November 3, 1998: US05830216 (155 worldwide citation)

A set of instruments and a surgical technique facilitate precise orientation of the femoral implant. Precision is aided by decoupling the determination of A/P placement, valgus angle, and external rotation into three discrete steps. In this way, a surgeon's full concentration can be directed to each ...


9
Ingegerg Hellstrom, Karl Erik Hellstrom, Kim Folger Bruce, George J Schreiber: Antibody conjugates reactive with human carcinomas. Bristol Myers Squibb Company, Merchant Gould Smith Welter and Schmidt, February 9, 1999: US05869045 (154 worldwide citation)

The present invention relates to novel antibodies, antibody fragments and antibody conjugates and single-chain immunotoxins reactive with human carcinoma cells. More particularly, the antibodies, conjugates and single-chain immunotoxins of the invention include: a murine monoclonal antibody, BR96; a ...


10
Peter S Linsley, Jeffrey A Ledbetter, Nitin K Damle, William Brady: Chimeric CTLA4 receptor and methods for its use. Bristol Myers Squibb Co, Merchant Gould Smith Edell Welter & Schmidt, July 18, 1995: US05434131 (152 worldwide citation)

The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the so ...



Click the thumbnails below to visualize the patent trend.